Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P. Bhatt, Raolat M. Abdulai, Naimish Patel et al.|New England Journal of Medicine|2023Cited by 452
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Dan V. Nicolau et al.|The Lancet Respiratory Medicine|2021Cited by 434
Benralizumab for the Prevention of COPD ExacerbationsGerard J. Criner, Ubaldo J. Martin, Maria Jison et al.|New England Journal of Medicine|2019Cited by 329
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al.|The Lancet|2021Cited by 310
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 InflammationSurya P. Bhatt, Lacey B. Robinson, Klaus F. Rabe et al.|New England Journal of Medicine|2024Cited by 240